BRAF and colorectal carcinoma: MSS CRC with BRAF mutations generally have a poor prognosis, while recent studies show that MSI is significant for immunotherapy, as microsatellite-unstable cancers respond well to PD-1 inhibitors in patients who have failed conventional therapies [46].